

Trying 3106016892...Open

```
Welcome to STN International! Enter x:x  
LOGINID:ssspta1202txn  
PASSWORD:  
TERMINAL (ENTER 1, 2, 3, OR ?):2
```

* * * * * * * * * * * * * * * Welcome to STN International * * * * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Sep 29 The Philippines Inventory of Chemicals and Chemical Substances (PICCS) has been added to CHEMLIST
NEWS 3 Oct 27 New Extraction Code PAX now available in Derwent Files
NEWS 4 Oct 27 SET ABBREVIATIONS and SET PLURALS extended in Derwent World Patents Index files
NEWS 5 Oct 27 Patent Assignee Code Dictionary now available in Derwent Patent Files
NEWS 6 Oct 27 Plasdoc Key Serials Dictionary and Echoing added to Derwent Subscriber Files WPIDS and WPIX
NEWS 7 Nov 29 Derwent announces further increase in updates for DWPII
NEWS 8 Dec 5 French Multi-Disciplinary Database PASCAL Now on STN
NEWS 9 Dec 5 Trademarks on STN - New DEMAS and EUMAS Files
NEWS 10 Dec 15 2001 STN Pricing
NEWS 11 Dec 17 Merged CEABA-VTB for chemical engineering and biotechnology
NEWS 12 Dec 17 Corrosion Abstracts on STN
NEWS 13 Dec 17 SYNTHLINE from Prous Science now available on STN
NEWS 14 Dec 17 The CA Lexicon available in the CAPLUS and CA files
NEWS 15 Jan 05 AIDSLINE is being removed from STN

NEWS EXPRESS FREE UPGRADE 5.0e FOR STN EXPRESS 5.0 WITH DISCOVER!
(WINDOWS) NOW AVAILABLE

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS INTER General Internet Information

NEWS LOGIN Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:05:32 ON 09 JAN 2001

=> file req

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

09/ 582,442

| FULL ESTIMATED COST | ENTRY | SESSION |
|---------------------|-------|---------|
| | 0.15 | 0.15 |

FILE 'REGISTRY' ENTERED AT 10:05:38 ON 09 JAN 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 8 JAN 2001 HIGHEST RN 313216-31-8
DICTIONARY FILE UPDATES: 8 JAN 2001 HIGHEST RN 313216-31-8

TSCA INFORMATION NOW CURRENT THROUGH July 8, 2000

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


Structure search limits have been increased. See HELP SLIMIT
for details.

=>
Uploading 582442.str

L1 STRUCTURE uploaded

=> d 11

L1 HAS NO ANSWERS
L1 STR



G1 CH2, SO2

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 10:06:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 245 TO ITERATE

100.0% PROCESSED 245 ITERATIONS 18 ANSWERS
SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3961 TO 5839
PROJECTED ANSWERS: 106 TO 614

L2 18 SEA SSS SAM L1

=> d scan 12

L2 18 ANSWERS REGISTRY COPYRIGHT 2001 ACS
 IN Piperazinone, 4-[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-, monohydrochloride (9CI)
 MF C23 H27 Cl N4 O3 S . Cl H

Double bond geometry as shown.



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s 11 ful

FULL SEARCH INITIATED 10:06:40 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 4494 TO ITERATE

100.0% PROCESSED 4494 ITERATIONS
 SEARCH TIME: 00.00.04

375 ANSWERS

L3 375 SEA SSS FUL L1

=> file caplus

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 133.87 | 134.02 |

FILE 'CAPLUS' ENTERED AT 10:06:53 ON 09 JAN 2001
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1967 - 9 Jan 2001 VOL 134 ISS 3
 FILE LAST UPDATED: 8 Jan 2001 (20010108/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Now you can extend your author, patent assignee, patent information, and title searches back to 1907. The records from 1907-1966 now have this searchable data in CAOLD. You now have electronic access to all of CA: 1907 to 1966 in CAOLD and 1967 to the present in CAPLUS on STN.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

=> s 13

L4 8 L3


=> d 14 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 8 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 1999:511143 CAPLUS
 DOCUMENT NUMBER: 131:170361
 TITLE: Preparation of sulfonamides as inhibitors of activated blood coagulation factor X
 INVENTOR(S): Tawada, Hiroyuki; Itoh, Fumio; Banno, Hiroshi; Terashita, Zenichi
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 187 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|--|----------|-----------------|----------|
| WO 9940075 | A1 | 19990812 | WO 1999-JP470 | 19990204 |
| W: | AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 AU 9922988 A1 19990823 AU 1999-22988 19990204
 JP 2000204081 A2 20000725 JP 1999-27053 19990204
 EP 1054005 A1 20001122 EP 1999-902829 19990204
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 PRIORITY APPLN. INFO.: JP 1998-24833 19980205
 JP 1998-317205 19981109
 WO 1999-JP470 19990204
 OTHER SOURCE(S): MARPAT 131:170361
 GI



- AB The title compds. I [R1 represents a hydrocarbyl or heterocyclic group each optionally substituted; the ring A represents a divalent nitrogen-contg. heterocycle group optionally further substituted; X' represents optionally substituted alkylene; Y represents an optionally substituted divalent cyclic group; X represents a bond or optionally substituted alkylene; and Z represents optionally substituted amino, optionally substituted imidoyl, or an optionally substituted nitrogen-contg. heterocyclic group] are prep'd. Formulations contg. a compd. of this invention are given. In a test for inhibiting activity of title compds. against activated blood coagulation factor X, 1-(4-amidinobenzyl)-4-(6-chloronaphthalene-2-sulfonyl)-2-piperazinone hydrochloride showed IC50 of 0.05 .mu.M.
- IT 229646-37-1P 239071-44-4P 239071-46-6P
 239071-47-7P 239071-48-8P 239071-50-2P
 239071-51-3P 239071-52-4P 239071-53-5P
 239071-54-6P 239071-55-7P 239071-62-6P
 239071-63-7P 239071-64-8P 239071-65-9P
 239071-66-0P 239071-67-1P 239071-68-2P
 239071-69-3P 239071-70-6P 239071-71-7P
 239071-79-5P 239071-81-9P 239071-82-0P
 239071-83-1P 239071-85-3P 239071-86-4P
 239071-87-5P 239071-88-6P 239071-92-2P
 239071-93-3P 239071-94-4P 239071-97-7P
 239071-98-8P 239071-99-9P 239072-00-5P
 239072-01-6P 239072-02-7P 239072-03-8P
 239072-05-0P 239072-23-2P 239072-29-8P
 239072-30-1P 239072-31-2P 239072-32-3P
 239072-33-4P 239072-34-5P 239072-35-6P
 239072-36-7P 239072-37-8P 239072-38-9P
 239072-39-0P 239072-40-3P 239072-41-4P
 239072-42-5P 239072-43-6P 239072-44-7P
 239072-45-8P 239072-46-9P 239072-47-0P
 239072-48-1P 239072-49-2P 239072-50-5P

239072-51-6P 239072-52-7P 239072-53-8P
 239072-54-9P 239072-57-2P 239072-58-3P
 239072-60-7P 239072-62-9P 239072-63-0P
 239072-64-1P 239072-65-2P 239072-66-3P
 239072-67-4P 239072-68-5P 239072-69-6P
 239074-62-5P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of sulfonamides as inhibitors of activated blood coagulation factor X)

RN 229646-37-1 CAPLUS

CN Piperazinone,


4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 239071-44-4 CAPLUS

CN Piperazinone,

4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239071-46-6 CAPLUS


CN Piperazinone, 4-[(1E)-2-(4-chlorophenyl)ethenylsulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 239071-47-7 CAPLUS
 CN Piperazinone, 4-[(4-ethenylphenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 239071-48-8 CAPLUS
 CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[4-hydroxy-1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 239071-50-2 CAPLUS
 CN Piperazinone,
 4-[(4-ethenylphenyl)sulfonyl]-1-[[4-hydroxy-1-(4-pyridinyl)-


4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 239071-51-3 CAPLUS

CN Piperazinone,

4-[(4-ethenylphenyl)sulfonyl]-1-[[4-hydroxy-1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239071-52-4 CAPLUS


CN Piperazinone,

4-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]-1-[[4-hydroxy-1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 239071-53-5 CAPLUS


CN Piperazinone, 1-[[4-(acetyloxy)-1-(4-pyridinyl)-4-piperidinyl]methyl]-4-[(6-chloro-2-naphthalenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 239071-54-6 CAPLUS
 CN Piperazinone, 1-[(4-(acetyloxy)-1-(4-pyridinyl)-4-piperidinyl)methyl]-4-[(4-ethenylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 239071-55-7 CAPLUS
 CN Piperazinone, 1-[(4-(acetyloxy)-1-(4-pyridinyl)-4-piperidinyl)methyl]-4-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 239071-62-6 CAPLUS
 CN 4-Piperidinecarboxylic acid, 4-[(4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl)methyl]-1-(4-pyridinyl)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239071-63-7 CAPLUS


CN 4-Piperidinecarboxylic acid, 4-[{[4-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]-2-oxo-1-piperazinyl]methyl}-1-(4-pyridinyl)-, methyl ester
(9CI) (CA INDEX NAME)

RN 239071-64-8 CAPLUS


CN Piperazinone,
4-[{(6-chloro-2-naphthalenyl)sulfonyl]-1-[{4-(hydroxymethyl)-1-(4-pyridinyl)-4-piperidinyl]methyl}- (9CI) (CA INDEX NAME)

RN 239071-65-9 CAPLUS


CN 4-Piperidinecarboxylic acid, 4-[{[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl]methyl}-1-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 239071-66-0 CAPLUS
 CN 4-Piperidinecarboxamide,
 4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl]methyl]-N,N-dimethyl-1-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 239071-67-1 CAPLUS
 CN 4-Piperidinecarboxamide,
 4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl]methyl]-N-methyl-1-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 239071-68-2 CAPLUS
 CN 4-Piperidinecarboxamide,
 4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl]methyl]-1-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 239071-69-3 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[4-hydroxy-1-(1-oxido-4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 239071-70-6 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl)methyl]-1-(1-oxido-4-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 239071-71-7 CAPLUS

CN 1-Piperazineacetonitrile, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-.alpha.-[1-(4-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 239071-79-5 CAPLUS

CN Piperazinone, 4-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 239071-81-9 CAPLUS

CN Piperazinone,
4-[(5-chloro-2-benzofuranyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl


RN 239071-82-0 CAPLUS

CN Piperazinone, 4-[(5-(4-chlorophenyl)-2-thienyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 239071-83-1 CAPLUS


CN Piperazinone, 4-[(5-ethenyl-2-thienyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 239071-85-3 CAPLUS

CN Piperazinone, 4-[(6-chloro-3,4-dihydro-2-naphthalenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 239071-86-4 CAPLUS

CN Piperazinone, 4-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239071-87-5 CAPLUS

CN Piperazinone,

4-[{(6-fluoro-2-naphthalenyl)sulfonyl}-1-{[1-(4-pyridinyl)-4-piperidinyl]methyl}-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239071-88-6 CAPLUS

CN Piperazinone,


4-[{(6-methyl-2-naphthalenyl)sulfonyl}-1-{[1-(4-pyridinyl)-4-piperidinyl]methyl}-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 239071-92-2 CAPLUS


CN Piperazinone, 4-[(7-bromo-2H-1-benzopyran-3-yl)sulfonyl]-1-[(4-hydroxy-1-(4-pyridinyl)-4-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 239071-93-3 CAPLUS


CN Piperazinone, 4-[(7-chloro-6-fluoro-2H-1-benzopyran-3-yl)sulfonyl]-1-[(4-hydroxy-1-(4-pyridinyl)-4-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



HCl


RN 239071-94-4 CAPLUS

CN Piperazinone,

4-[(7-chloro-4-hydroxy-2-oxo-2H-1-benzopyran-3-yl)sulfonyl]-
1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)


RN 239071-97-7 CAPLUS

CN Piperazinone, 4-[(7-chloro-2-oxo-2H-1-benzopyran-3-yl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 239071-98-8 CAPLUS

CN 1-Piperazinepropanoic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-.beta.-[1-(4-pyridinyl)-4-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 239071-99-9 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[(4-hydroxy-1-(4-pyrimidinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 239072-00-5 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(6-chloro-4-pyrimidinyl)-4-hydroxy-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 239072-01-6 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(2-chloro-4-pyrimidinyl)-4-hydroxy-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 239072-02-7 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[4-hydroxy-1-[(phenylmethyl)amino]-4-pyrimidinyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 239072-03-8 CAPLUS


CN Piperazinone, 4-[(4-ethenylphenyl)sulfonyl]-1-[(4-hydroxy-1-(4-pyrimidinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 239072-05-0 CAPLUS

CN Piperazinone, 4-[(4-(1H-imidazol-1-ylmethyl)phenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●2 HCl

RN 239072-23-2 CAPLUS

CN Piperazinone,

4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[2-[1-(4-pyridinyl)-
4-piperidinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239072-29-8 CAPLUS

CN Piperazinone,


4-[(4-(1-methylethenyl)phenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 239072-30-1 CAPLUS

CN Piperazinone,

4-[(4-(1-methylethenyl)phenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239072-31-2 CAPLUS

CN Piperazinone,

4-[(4-(1E)-1-propenylphenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 239072-32-3 CAPLUS

CN Piperazinone,
4-[(4-(1E)-1-propenylphenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl


RN 239072-33-4 CAPLUS

CN Piperazinone, 4-[(4-iodophenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 239072-34-5 CAPLUS


CN Piperazinone, 4-[(4-iodophenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 239072-35-6 CAPLUS

CN Piperazinone, 4-[(3-bromophenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 239072-36-7 CAPLUS


CN Piperazinone, 4-[(3-bromophenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 239072-37-8 CAPLUS


CN Piperazinone,
4-[(2-oxo-2H-1-benzopyran-6-yl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 239072-38-9 CAPLUS

CN Piperazinone,


4-{(2-oxo-2H-1-benzopyran-6-yl)sulfonyl}-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 239072-39-0 CAPLUS

CN Piperazinone, 4-{(7-chloro-4-oxo-4H-1-benzopyran-3-yl)sulfonyl}-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 239072-40-3 CAPLUS


CN Piperazinone, 4-{(7-chloro-4-oxo-4H-1-benzopyran-3-yl)sulfonyl}-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 239072-41-4 CAPLUS

CN Piperazinone, 4-([1,1'-biphenyl]-4-ylsulfonyl)-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 239072-42-5 CAPLUS


CN Piperazinone, 4-([1,1'-biphenyl]-4-ylsulfonyl)-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 239072-43-6 CAPLUS


CN Piperazinone, 4-([1,1'-biphenyl]-3-ylsulfonyl)-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 239072-44-7 CAPLUS


CN Piperazinone, 4-[(3'-chloro[1,1'-biphenyl]-3-yl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 239072-45-8 CAPLUS

CN Piperazinone, 4-[(4-ethynylphenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 239072-46-9 CAPLUS


CN Piperazinone, 4-[(4-ethynylphenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 239072-47-0 CAPLUS

CN Piperazinone, 4-[(3-ethynylphenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 239072-48-1 CAPLUS

CN Piperazinone, 4-[(3-ethynylphenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239072-49-2 CAPLUS

CN Piperazinone, 4-[[4-[(1E)-2-chloroethenyl]phenyl]sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 239072-50-5 CAPLUS

CN Piperazinone, 4-[{4-[{(1E)-2-chloroethenyl}phenyl]sulfonyl}-1-{[1-(4-pyridinyl)-4-piperidinyl]methyl}-, monohydrochloride (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl


RN 239072-51-6 CAPLUS

CN Piperazinone, 4-[{(4-ethylphenyl)sulfonyl}-1-{[1-(4-pyridinyl)-4-piperidinyl]methyl}- (9CI) (CA INDEX NAME)



RN 239072-52-7 CAPLUS


CN Piperazinone, 4-[{(4-ethylphenyl)sulfonyl}-1-{[1-(4-pyridinyl)-4-piperidinyl]methyl}-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 239072-53-8 CAPLUS

CN Piperazinone, 4-[(3-ethenylphenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 239072-54-9 CAPLUS


CN Piperazinone, 4-[(3-ethenylphenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 239072-57-2 CAPLUS

CN Piperazinone, 4-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]-1-[(4-(1-oxopropoxy)-1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 239072-58-3 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[(4-methoxy-1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 239072-60-7 CAPLUS

CN Methanesulfonamide, N-[4-[(4-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]-2-oxo-1-piperazinyl)methyl]-1-(4-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 239072-62-9 CAPLUS

CN Glycine, N-[(4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl)methyl]-1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 239072-63-0 CAPLUS


CN Glycine, N-[4-[(4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl)methyl]-1-(4-pyridinyl)-4-piperidinyl]carbonyl-, ethyl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 239072-64-1 CAPLUS

CN .beta.-Alanine, N-[4-[(4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl)methyl]-1-(4-pyridinyl)-4-piperidinyl]carbonyl-, ethyl ester
(9CI) (CA INDEX NAME)




RN 239072-65-2 CAPLUS

CN Butanoic acid, 4-[[[4-[(4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl)methyl]-1-(4-pyridinyl)-4-piperidinyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 239072-66-3 CAPLUS

CN Glycine, N-[4-[(4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl)methyl]-1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 239072-67-4 CAPLUS

CN .beta.-Alanine, N-[4-[(4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl)methyl]-1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 239072-68-5 CAPLUS

CN Butanoic acid, 4-[[[4-[(4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl)methyl]-1-(4-pyridinyl)-4-piperidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 239072-69-6 CAPLUS

CN Carbamic acid, [4-[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl]methyl]-1-(4-pyridinyl)-4-piperidinyl-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 239074-62-5 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[(4-hydroxy-1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



IT 229646-35-9P 239073-05-3P 239073-27-9P

239073-28-0P 239073-46-2P 239073-50-8P


239073-69-9P 239074-19-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of sulfonamides as inhibitors of activated blood coagulation factor X)

RN 229646-35-9 CAPLUS


CN Piperazinone, 4-[(1E)-2-(4-chlorophenyl)ethenylsulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 239073-05-3 CAPLUS

CN Piperazinone, 4-[(4-ethenylphenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 239073-27-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[(4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl)methyl]-1-(4-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 239073-28-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[(4-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]-2-oxo-1-piperazinyl)methyl]-1-(4-pyridinyl)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239073-46-2 CAPLUS
 CN Piperazinone, 4-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 239073-50-8 CAPLUS
 CN Piperazinone,
 4-[(5-chloro-2-benzofuranyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 239073-69-9 CAPLUS
 CN Piperazinone, 4-[(4-(1H-imidazol-1-ylmethyl)phenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 239074-19-2 CAPLUS

CN Piperazinone,
4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[2-[1-(4-pyridinyl)-
4-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

15

REFERENCE(S):

- (1) Takeda Chemical Industries Ltd; JP 09316059 A
CAPLUS
- (2) Takeda Chemical Industries Ltd; CN 1069730 A
CAPLUS
- (3) Takeda Chemical Industries Ltd; US 5294713 A
CAPLUS
- (4) Takeda Chemical Industries Ltd; EP 529858 A1
CAPLUS
- (5) Takeda Chemical Industries Ltd; EP 822931 A1
CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:460402 CAPLUS

DOCUMENT NUMBER: 131:87833

TITLE: Preparation of aromatic compounds having cyclic amino or salts thereof as FXa inhibitors

INVENTOR(S): Nishida, Hidemitsu; Hosaka, Yoshitaka; Miyazaki, Yutaka; Matsusue, Tomokazu; Mukaihira, Takafumi

PATENT ASSIGNEE(S): Mochida Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 218 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 9933805 | A1 | 19990708 | WO 1998-JP6002 | 19981228 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 9916923 | A1 | 19990719 | AU 1999-16923 | 19981228 |
| EP 1048652 | A1 | 20001102 | EP 1998-961642 | 19981228 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| PRIORITY APPLN. INFO.: | | | JP 1997-367538 | 19971226 |

JP 1998-311491 19981030
 WO 1998-JP6002 19981228

OTHER SOURCE(S): MARPAT 131:87833
 GI



AB Title Compds. [I; G1, X and Y represent each CH or N; Z1 represents -SO₂CH:CH- or -SO₂-; Q represents aryl or heteroaryl; and R2 to R9 represent each hydrogen or a substituent; n = 0-1] and salts thereof which specifically inhibit FXa, exert a potent anticoagulant effect and thus are useful as medicinal compns. are prep'd. Title compd. I (G1 = N; X = N; Y = CH; n = 0; R2 = H; R3 = H; R4 = H; R5 = H; R6 = H; R7 = H; R8 = H; R9 = H; Z1 = (E)-SO₂CH:CH; Q = 4-ClC₆H₄) was prep'd. in two steps.

IT 229646-14-4P 229646-15-5P 229646-16-6P
 229646-17-7P 229646-18-8P 229646-19-9P
 229646-20-2P 229646-21-3P 229646-22-4P
 229646-23-5P 229646-24-6P 229646-25-7P
 229646-26-8P 229646-27-9P 229646-28-0P
 229646-29-1P 229646-30-4P 229646-32-6P
 229646-33-7P 229646-34-8P 229646-35-9P
 229646-36-0P 229646-37-1P 229646-38-2P
 229646-39-3P 229646-40-6P 229646-41-7P
 229646-42-8P 229646-43-9P 229646-44-0P
 229646-45-1P 229646-46-2P 229646-47-3P
 229646-48-4P 229646-49-5P 229646-50-8P
 229646-51-9P 229646-52-0P 229646-53-1P
 229646-54-2P 229646-55-3P 229646-56-4P
 229646-57-5P 229646-58-6P 229646-59-7P
 229646-60-0P 229646-61-1P 229646-62-2P
 229646-63-3P 229646-64-4P 229646-65-5P
 229646-66-6P 229646-67-7P 229646-68-8P
 229646-69-9P 229646-70-2P 229646-71-3P
 229646-72-4P 229646-73-5P 229646-74-6P
 229646-75-7P 229646-76-8P 229646-77-9P
 229646-78-0P 229646-79-1P 229646-80-4P
 229646-81-5P 229646-82-6P 229646-83-7P
 229646-84-8P 229646-85-9P 229646-86-0P
 229646-87-1P 229646-88-2P 229646-89-3P
 229646-90-6P 229646-91-7P 229646-92-8P
 229646-93-9P 229646-94-0P 229646-95-1P

229646-96-2P 229646-97-3P 229646-98-4P

229646-99-5P 229647-00-1P 229647-01-2P

229647-02-3P 229647-03-4P 229647-04-5P


229647-05-6P 229955-03-7P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. of arom. compds. having cyclic amino or salts thereof as FXa inhibitors)

RN 229646-14-4 CAPLUS


CN Piperazine, 1-[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 229646-15-5 CAPLUS

CN Piperazine, 1-(2-naphthalenylsulfonyl)-4-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 229646-16-6 CAPLUS

CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 229646-17-7 CAPLUS

CN Piperazine, 1-[(6-bromo-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-18-8 CAPLUS

CN Piperazine, 1-(benzo[b]thien-2-ylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-19-9 CAPLUS

CN Piperazine, 1-[(5-fluorobenzo[b]thien-2-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 229646-20-2 CAPLUS


CN Piperazine, 1-[(6-chlorobenzo[b]thien-2-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 229646-21-3 CAPLUS

CN Piperazine,


1-[4-methoxybenzo[b]thien-2-yl]sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 229646-22-4 CAPLUS


CN Piperazine,

1-[6-methoxybenzo[b]thien-2-yl]sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 229646-23-5 CAPLUS

CN Benzo[b]thiophene-3-carboxylic acid, 2-[[4-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-1-piperazinyl]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 229646-24-6 CAPLUS

CN Piperazine, 1-[(1-(4-pyridinyl)-4-piperidinylmethyl)-4-[3-(trifluoromethyl)benzo[b]thien-2-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 229646-25-7 CAPLUS

CN Piperazine,
1-[(3-nitrobenzo[b]thien-2-yl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinylmethyl)- (9CI) (CA INDEX NAME)


RN 229646-26-8 CAPLUS

CN Piperazine, 1-(2-benzofuranyl sulfonyl)-4-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 229646-27-9 CAPLUS

CN Piperazine, 1-[(5-chloro-2-benzofuranyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 229646-28-0 CAPLUS

CN Piperazine, 1-[(2-bromo-6-benzothiazolyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 229646-29-1 CAPLUS

CN Piperazine, 1-[(1,1'-biphenyl)-4-ylsulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 229646-30-4 CAPLUS

CN Benzoic acid, 4-chloro-3-[[4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-1-piperazinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 229646-32-6 CAPLUS

CN Benzeneacetic acid,
4-chloro-3-[[4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-1-piperazinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 229646-33-7 CAPLUS

CN Acetamide, N-[6-[[4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-1-piperazinyl]sulfonyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 229646-34-8 CAPLUS


CN Piperazine, 1-[(5-amino-2-naphthalenyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 229646-35-9 CAPLUS


CN Piperazinone, 4-[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229646-36-0 CAPLUS


CN Piperazinone, 4-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 229646-37-1 CAPLUS


CN Piperazinone,

4-[{(6-chloro-2-naphthalenyl)sulfonyl}-1-{[1-(4-pyridinyl)-4-piperidinyl]methyl}- (9CI) (CA INDEX NAME)



RN 229646-38-2 CAPLUS


CN Piperazinone, 4-(2-naphthalenylsulfonyl)-1-{[1-(4-pyridinyl)-4-piperidinyl]methyl}- (9CI) (CA INDEX NAME)




RN 229646-39-3 CAPLUS

CN Piperazinone,


4-[{(6-methyl-2-naphthalenyl)sulfonyl}-1-{[1-(4-pyridinyl)-4-piperidinyl]methyl}- (9CI) (CA INDEX NAME)




RN 229646-40-6 CAPLUS
CN Piperazinone, 4-[(6-cyano-2-naphthalenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 229646-41-7 CAPLUS
CN Piperazinone,
4-[(6-hydroxy-2-naphthalenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 229646-42-8 CAPLUS
CN Piperazinone,
4-[(1-fluoro-2-naphthalenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 229646-43-9 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 229646-44-0 CAPLUS

CN 2-Piperazinemethanol, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 229646-45-1 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 229646-46-2 CAPLUS

CN 2-Piperazinepropanoic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-.beta.-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 229646-47-3 CAPLUS

CN 2-Piperazinecarboxamide, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-48-4 CAPLUS

CN 2-Piperazinecarboxamide, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[2-(ethylthio)ethyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-49-5 CAPLUS

CN Piperazine, 2-acetyl-4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 229646-50-8 CAPLUS

CN 2-Piperazinecarboxamide, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-N,N-dimethyl-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 229646-51-9 CAPLUS

CN 2-Piperazinecarboxylic acid,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
 [[1-(4-pyridinyl)-4-piperidinyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 229646-52-0 CAPLUS

CN 2-Piperazinecarboxylic acid,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
 [[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-53-1 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-(hydroxymethyl)-1-
 [[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 229646-54-2 CAPLUS


CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-(methoxymethyl)-1-
 [[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 229646-55-3 CAPLUS

CN Piperazinone,

6-[(acetyloxy)methyl]-4-[(6-chloro-2-naphthalenyl)sulfonyl]-
1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 229646-56-4 CAPLUS

CN 2-Piperazinecarboxylic acid,

4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-
6-oxo-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-, ethyl ester (9CI) (CA
INDEX NAME)


Double bond geometry as shown.



RN 229646-57-5 CAPLUS


CN 2-Piperazinecarboxylic acid,
4-[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-
6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 229646-58-6 CAPLUS

CN 2-Piperazinecarboxamide,
4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-59-7 CAPLUS

CN 2-Piperazinecarboxaldehyde,

4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, 2-oxime (9CI) (CA INDEX NAME)


RN 229646-60-0 CAPLUS

CN Morpholine, 4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-2-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 229646-61-1 CAPLUS

CN 2-Piperazinecarboxamide, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-N,N-dimethyl-6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-62-2 CAPLUS

CN 2-Piperazinecarboxamide,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-N-methoxy-6-
 oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 229646-63-3 CAPLUS


CN 4-Piperidinol, 1-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-2-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 229646-64-4 CAPLUS


CN Piperazinone,
 6-(aminomethyl)-4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-

(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-65-5 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-(4-morpholinylmethyl)-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 229646-66-6 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-[(dimethylamino)methyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 229646-67-7 CAPLUS


CN Acetamide, N-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-2-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 229646-68-8 CAPLUS


CN Methanesulfonamide,

N-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-2-piperazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-69-9 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-[(4-hydroxy-1-piperidinyl)methyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 229646-70-2 CAPLUS

CN Piperazinone, 6-(hydroxymethyl)-4-(2-naphthalenylsulfonyl)-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 229646-71-3 CAPLUS


CN Piperazinone, 6-[(acetyloxy)methyl]-4-(2-naphthalenylsulfonyl)-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 229646-72-4 CAPLUS

CN 2-Piperazinecarboxylic acid,
4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
[(1-(4-pyridinyl)-4-piperidinyl)methyl]-, ethyl ester, (2R)- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 229646-73-5 CAPLUS

CN 2-Piperazinecarboxylic acid,
4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, ethyl ester, (2S)- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 229646-74-6 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-(methoxymethyl)-1-
[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (6R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229646-75-7 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-(methoxymethyl)-1-
[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229646-76-8 CAPLUS


CN 2-Piperazinecarboxylic acid,
4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 229646-77-9 CAPLUS


CN 2-Piperazinecarboxylic acid,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
 [[1-(4-pyridinyl)-4-piperidinyl]methyl]-, propyl ester (9CI) (CA INDEX
 NAME)




RN 229646-78-0 CAPLUS

CN 2-Piperazinecarboxylic acid,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
 [[1-(4-pyridinyl)-4-piperidinyl]methyl]-, propyl ester, (2R)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 229646-79-1 CAPLUS
 CN 2-Piperazinecarboxylic acid,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
 [[1-(4-pyridinyl)-4-piperidinyl]methyl]-, 1-methylethyl ester (9CI) (CA
 INDEX NAME)




RN 229646-80-4 CAPLUS
 CN 2-Piperazinecarboxylic acid,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
 [[1-(4-pyridinyl)-4-piperidinyl]methyl]-, 1-methylethyl ester, (2R)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229646-81-5 CAPLUS
 CN 2-Piperazinecarboxylic acid,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
 [[1-(4-pyridinyl)-4-piperidinyl]methyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)



RN 229646-82-6 CAPLUS
 CN Piperazinone,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6,6-dimethyl-1-[[1-(4-
 pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-83-7 CAPLUS
 CN Piperazine, 1-[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 229646-14-4
 CMF C23 H29 Cl N4 O2 S

Double bond geometry as shown.



CM 2

CRN 75-75-2
 CMF C H4 O3 S




RN 229646-84-8 CAPLUS
 CN Piperazinone, 4-[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 229646-35-9
 CMF C23 H27 Cl N4 O3 S

Double bond geometry as shown.




CM 2

CRN 75-75-2
CMF C H4 O3 S


RN 229646-85-9 CAPLUS
 CN Piperazinone,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 229646-37-1
CMF C25 H27 Cl N4 O3 S

CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 229646-86-0 CAPLUS

CN 2-Piperazinecarboxylic acid,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
 [[1-(4-pyridinyl)-4-piperidinyl]methyl]-, ethyl ester,
 monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 229646-51-9


CMF C28 H31 Cl N4 O5 S



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 229646-87-1 CAPLUS

CN 2-Piperazinecarboxylic acid,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
 [[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monomethanesulfonate (9CI) (CA
 INDEX NAME)


CM 1

CRN 229646-52-0


CMF C26 H27 Cl N4 O5 S



CM 2


CRN 75-75-2
CMF C H4 O3 SRN 229646-88-2 CAPLUS
CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-(hydroxymethyl)-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monomethanesulfonate (salt)
(9CI) (CA INDEX NAME)

CM 1

CRN 229646-53-1
CMF C26 H29 Cl N4 O4 S

CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 229646-89-3 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-(methoxymethyl)-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 229646-54-2


CMF C27 H31 Cl N4 O4 S



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 229646-90-6 CAPLUS

CN Piperazinone,
6-[(acetoxy)methyl]-4-[(6-chloro-2-naphthalenyl)sulfonyl]-
1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monomethanesulfonate (9CI)
(CA INDEX NAME)

CM 1

CRN 229646-55-3


CMF C28 H31 Cl N4 O5 S



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 229646-91-7 CAPLUS


CN 2-Piperazinecarboxylic acid,
 4-[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-
 6-oxo-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-, ethyl ester,
 monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 229646-56-4

CMF C26 H31 Cl N4 O5 S

Double bond geometry as shown.



CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 229646-92-8 CAPLUS
 CN 2-Piperazinecarboxylic acid,
 4-[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-
 6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monomethanesulfonate
 (9CI) (CA INDEX NAME)

CM 1

CRN 229646-57-5
CMF C24 H27 Cl N4 O5 S


Double bond geometry as shown.



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 229646-93-9 CAPLUS

CN Morpholine, 4-[{4-[{(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-2-piperazinyl]carbonyl}]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 229646-60-0

CMF C30 H34 Cl N5 O5 S




CM 2

CRN 75-75-2
CMF C H4 O3 S


RN 229646-94-0 CAPLUS
 CN Piperazinone,
 6-(aminomethyl)-4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[(1-
 (4-pyridinyl)-4-piperidinyl)methyl]-, monomethanesulfonate (9CI) (CA
 INDEX NAME)

CM 1

CRN 229646-64-4
CMF C26 H30 Cl N5 O3 S

CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 229646-95-1 CAPLUS
 CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-(4-morpholinylmethyl)-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 229646-65-5
 CMF C30 H36 Cl N5 O4 S




CM 2

CRN 75-75-2
 CMF C H4 O3 S




RN 229646-96-2 CAPLUS
 CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-[(dimethylamino)methyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 229646-66-6
CMF C28 H34 Cl N5 O3 S


CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 229646-97-3 CAPLUS


CN Acetamide, N-[(4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-2-piperazinyl)methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 229646-67-7
CMF C28 H32 Cl N5 O4 S

CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 229646-98-4 CAPLUS
 CN Methanesulfonamide,
 N-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-2-piperazinyl]methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 229646-68-8
 CMF C27 H32 Cl N5 O5 S2



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 229646-99-5 CAPLUS
 CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-[(4-hydroxy-1-piperidinyl)methyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 229646-69-9
CMF C31 H38 Cl N5 O4 S



CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 229647-00-1 CAPLUS
CN 2-Piperazinecarboxylic acid,
4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, ethyl ester, (2R)-,
monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 229646-72-4
CMF C28 H31 Cl N4 O5 S

Absolute stereochemistry.



CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 229647-01-2 CAPLUS
 CN 2-Piperazinecarboxylic acid,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
 [[1-(4-pyridinyl)-4-piperidinyl]methyl]-, ethyl ester, (2S)-,
 monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 229646-73-5
CMF C28 H31 Cl N4 O5 S

Absolute stereochemistry.




CM 2

CRN 75-75-2
CMF C H4 O3 SRN 229647-02-3 CAPLUS
CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-(methoxymethyl)-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (6R)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 229646-74-6
CMF C27 H31 Cl N4 O4 S


Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 229647-03-4 CAPLUS


CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-(methoxymethyl)-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (6S)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 229646-75-7

CMF C27 H31 Cl N4 O4 S


Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 229647-04-5 CAPLUS


CN 2-Piperazinecarboxylic acid,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
 [[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (2R)-, monomethanesulfonate
 (9CI) (CA INDEX NAME)

CM 1

CRN 229646-76-8

CMF C26 H27 Cl N4 O5 S


Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 229647-05-6 CAPLUS

CN 2-Piperazinecarboxylic acid,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-[
 {[1-(4-pyridinyl)-4-piperidinyl]methyl}-, propyl ester, (2R)-,
 monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 229646-78-0
 CMF C29 H33 Cl N4 O5 S

Absolute stereochemistry.



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 229955-03-7 CAPLUS

CN Piperazinone, 4-[(1E)-2-(4-chlorophenyl)ethenylsulfonyl]-6-(methoxymethyl)-1-[1-(4-pyridinyl)-4-piperidinyl]methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 229647-18-1P 229955-04-8P 229955-05-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of arom. compds. having cyclic amino or salts thereof as FXa
inhibitors)

RN 229647-18-1 CAPLUS

CN 2-Piperazinecarboxaldehyde,

4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229955-04-8 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-[(2,5-dioxo-1-pyrrolidinyl)methyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI)

(CA


INDEX NAME)



RN 229955-05-9 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-[[[(4-

methylphenyl)sulfonyl]oxy]methyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

15

REFERENCE(S):

- (1) Adir Et Co; FR 2601364 A CAPLUS
 - (2) Adir Et Co; EP 262993 A CAPLUS
 - (3) Adir Et Co; US 4820707 A CAPLUS
 - (6) Glaxo Group Ltd; EP 542363 A CAPLUS
 - (7) Glaxo Group Ltd; EP 612313 A CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:113671 CAPLUS

DOCUMENT NUMBER: 130:168388

TITLE: Pyridyl- and pyrimidyl-heterocyclic compounds inhibiting oxidosqualene cyclase

INVENTOR(S): Newcombe, Nicholas John; Johnson, Michael Clyde

PATENT ASSIGNEE(S): Zeneca Limited, UK

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|--|----------|-----------------|----------|
| WO 9906395 | A1 | 19990211 | WO 1998-GB2196 | 19980723 |
| W: | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, | | | |

CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 9885471 A1 19990222 AU 1998-85471 19980723
EP 1000057 A1 20000517 EP 1998-936494 19980723
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

PRIORITY APPLN. INFO.: GB 1997-15892 19970729
WO 1998-GB2196 19980723

OTHER SOURCE(S): MARPAT 130:168388
GI



AB The title compds. I [G = CH, N; R1 = H, halo, (1-6C)alkyl, halo(1-6C)alkyl, cyano, nitro, (1-6C)alkoxycarbonyl, NR3R4 (R3, R4 = H, (1-6C)alkyl), up to 3 R1 groups may be present; T1 = CH, N; T2, T3 = N,

CR (R = H, hydroxyl, (C1-4)alkyl); either ring contg. T2 or T3 is optionally substituted with an oxo group; R2 = H, (1-4C)alkyl; Q = SO₂, CO, CH₂; Ar =

five or six-membered heterocycle contg. up to 3 heteroatoms selected from nitrogen, oxygen and sulfur, Ph, phenyl(2-6C)alkenyl, naphthyl in which any Ar group is optionally substituted by one or more substituents selected from (1-6C)alkyl, halo, halo(1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkoxycarbonyl, cyano, (1-6C)alkylamido, nitro, NR3R4 (R3, R4 = H, (1-4C)alkyl) both T2 and T3 are not N and when T2 is CR then T1 is not CH], useful in inhibiting oxidosqualene cyclase (no data), were prepd.

E.g.,

1-(4-chlorophenylsulfonyl)-4-[1-(2-methylpyrimidin-4-yl)piperazin-4-ylmethyl]piperidine was prepd.

IT 220358-83-8P 220358-84-9P 220358-85-0P
220358-86-1P 220358-88-3P 220358-89-4P
220358-90-7P 220358-91-8P 220358-92-9P
220358-93-0P 220358-94-1P 220358-95-2P
220358-96-3P 220359-01-3P 220359-03-5P
220359-04-6P 220359-05-7P 220359-06-8P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of pyridyl- and pyrimidyl-heterocyclic compds. as inhibitors of


oxidosqualene cyclase)

RN 220358-83-8 CAPLUS


CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 220358-84-9 CAPLUS
 CN Piperazine, 1-[(1-(2-methyl-4-pyrimidinyl)-4-piperidinyl)methyl]-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 220358-85-0 CAPLUS
 CN Piperazine,
 1-[(4-fluorophenyl)sulfonyl]-4-[(1-(2-methyl-4-pyrimidinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 220358-86-1 CAPLUS
 CN Piperazine,
 1-[(4-methoxyphenyl)sulfonyl]-4-[(1-(2-methyl-4-pyrimidinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 220358-88-3 CAPLUS
 CN Piperazine,
 1-[[4-hydroxy-1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]methyl]-4-[(4-(trifluoromethyl)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 220358-89-4 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[(4-hydroxy-1-(2-methyl-4-pyrimidinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 220358-90-7 CAPLUS

CN Piperazine, 1-[(4-hydroxy-1-(2-methyl-4-pyrimidinyl)-4-piperidinyl)methyl]-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 220358-91-8 CAPLUS

CN Piperazine, 1-[(4-hydroxy-1-(2-methyl-4-pyrimidinyl)-4-piperidinyl)methyl]-4-[(4-methoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 220358-92-9 CAPLUS

CN Piperazine, 1-[(4-hydroxy-1-(2-methyl-4-pyrimidinyl)-4-piperidinyl)methyl]-4-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 220358-93-0 CAPLUS

CN Piperazine, 1-[(4-chlorophenyl)sulfonyl]-4-[{4-hydroxy-1-(2-methyl-4-pyrimidinyl)-4-piperidinyl}methyl]- (9CI) (CA INDEX NAME)




RN 220358-94-1 CAPLUS

CN Piperazine, 1-[(4-chlorophenyl)sulfonyl]-4-[{1-(2,6-dimethyl-4-pyrimidinyl)-4-piperidinyl}methyl]- (9CI) (CA INDEX NAME)




RN 220358-95-2 CAPLUS

CN Piperazinone,
4-[(4-bromophenyl)sulfonyl]-1-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

RN 220358-96-3 CAPLUS


CN Piperazinone, 4-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]methyl]-1-[(4-

(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 220359-01-3 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[(1-(6-methyl-4-pyrimidinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 220359-03-5 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[(1-(2-fluoro-4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 220359-04-6 CAPLUS

CN Piperazine, 1-[(4-(4-bromophenyl)sulfonyl)-4-[(1-(2,6-dimethyl-4-pyrimidinyl)-4-piperidinyl)methyl]methyl]- (9CI) (CA INDEX NAME)




RN 220359-05-7 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 220359-06-8 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[(1-(2-chloro-4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




IT 203522-53-6 220359-08-0

RL: RCT (Reactant)
(prepn. of pyridyl- and pyrimidyl-heterocyclic compds. as inhibitors
of
oxidosqualene cyclase)


RN 203522-53-6 CAPLUS

CN Piperazine, 1-[(4-chlorophenyl)sulfonyl]-4-[(1-(2,6-dimethyl-4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 220359-08-0 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[(1-(6-methyl-4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




IT 220359-13-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of pyridyl- and pyrimidyl-heterocyclic compds. as inhibitors
 of
 oxidosqualene cyclase)

RN 220359-13-7 CAPLUS

CN Piperazine, 1-[(1-(2-methyl-4-pyrimidinyl)-4-piperidinylmethyl)-4-[(4-(trifluoromethyl)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

6

REFERENCE(S):

- (1) Brown, G; WO 9706802 A 1997 CAPLUS
- (2) Brown, G; WO 9728128 A 1997 CAPLUS
- (3) Brown, G; WO 9806705 A 1998 CAPLUS
- (4) Brown, G; WO 9835956 A 1998 CAPLUS
- (5) Brown, G; WO 9835959 A 1998 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:568819 CAPLUS

DOCUMENT NUMBER: 129:189344

TITLE: 1-(Arylsulfonyl)-4-[(1-(4-pyridyl)piperazin-4-yl]carbonyl]piperazines and analogs useful as oxido-squalene cyclase inhibitors

INVENTOR(S): Brown, George Robert

PATENT ASSIGNEE(S): Zeneca Limited, UK

SOURCE: PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 9835956 | A1 | 19980820 | WO 1998-GB405 | 19980209 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, | | | | |

NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
 UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
 FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
 GA, GN, ML, MR, NE, SN, TD, TG
 AU 9859996 A1 19980908 AU 1998-59996 19980209
 EP 966460 A1 19991229 EP 1998-903174 19980209
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 ZA 9801177 A 19980813 ZA 1998-1177 19980212
 PRIORITY APPLN. INFO.: GB 1997-2946 19970213
 GB 1997-15734 19970726
 GB 1997-19237 19970911
 WO 1998-GB405 19980209

OTHER SOURCE(S): MARPAT 129:189344
 GI



AB This invention concerns heterocyclic compds. I [R = halo, cyano, NO₂, CO₂H, alkyl, alkoxy, alkanoyl, alkoxycarbonyl, haloalkyl; R1 = H, (di)(alkyl)amino, halo, cyano, NO₂, CO₂H, alkyl, alkoxy, alkanoyl, alkylthio, etc.; m = 1 or 2; A = bond or C1-4 alkylene; X, Y = N, CR₂; R₂ = H, alk(en/yn)yl; Z = N, CH; Q = (un)substituted heteroaryl, Ph, naphthyl, etc.; rings contg. X, Y, and Z may be substituted; with several provisos], which are useful for inhibiting oxido-squalene cyclase, processes for their prepn., and pharmaceutical compns. contg. them. The invention is also concerned with such heterocyclic compds. capable of inhibiting cholesterol biosynthesis, and hence lowering cholesterol levels

in blood plasma. The invention also relates to methods of using such compds. in diseases and medical conditions such as hypercholesterolemia and atherosclerosis. For instance, chlorination of 1-[(4-bromophenyl)sulfonyl]-4-[[1-(4-pyridyl)piperidin-4-yl]carbonyl]piperazine with N-chlorosuccinimide in MeCN gave title compd. II. The latter gave about 79% inhibition of rat microsomal oxido-squalene cyclase in vitro at 0.01 .mu.M, and likewise gave about 79% inhibition of rat cholesterol biosynthesis in vivo at 2 mg/kg orally. The compds. showed no overt toxicity at several multiples of the min. ID. Several std. pharmaceutical


formulations are described.

IT 211819-82-8P 211819-83-9P 211819-84-0P
 211819-86-2P 211819-87-3P 211819-88-4P
 211819-89-5P 211819-90-8P 211819-95-3P
 211819-96-4P

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of (arylsulfonyl)[(pyridylpiperazinyl)carbonyl]piperazines and analogs as oxido-squalene cyclase inhibitors)


RN 211819-82-8 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[(1-(3-chloro-4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 211819-83-9 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[(1-(3-bromo-4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 211819-84-0 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[(1-(5-chloro-2-methyl-4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 211819-86-2 CAPLUS


CN Piperazine,
 1-[(1-(5-bromo-2-methyl-4-pyridinyl)-4-piperidinyl)carbonyl]-4-
 [(4-bromophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 211819-87-3 CAPLUS
 CN Piperazine, 1-[(1-(3-chloro-4-pyridinyl)-4-piperidinyl]carbonyl]-4-[(3-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 211819-88-4 CAPLUS
 CN Piperazine, 1-[(1-(3-chloro-4-pyridinyl)-4-piperidinyl]carbonyl]-4-[(4-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 211819-89-5 CAPLUS
 CN Piperazine, 1-[(1-(3-chloro-4-pyridinyl)-4-piperidinyl]carbonyl]-4-[(4-methoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 211819-90-8 CAPLUS
 CN Piperazine, 1-[(1-(3-chloro-4-pyridinyl)-4-piperidinyl]carbonyl]-4-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 211819-95-3 CAPLUS
 CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(3-fluoro-4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 211819-96-4 CAPLUS
 CN Piperazine, 1-[[1-(3-fluoro-4-pyridinyl)-4-piperidinyl]carbonyl]-4-[(4-(trifluoromethyl)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)



IT 179050-10-3
 RL: RCT (Reactant)
 (starting material; prepn. of
 (arylsulfonyl)[(pyridylpiperazinyl)carbon
 yl]piperazines and analogs as oxido-squalene cyclase inhibitors)
 RN 179050-10-3 CAPLUS
 CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 1998:126242 CAPLUS
 DOCUMENT NUMBER: 128:192661

TITLE: Preparation of
 pyrimidinylpiperidinylcarbonylpiperazin
 es and related compounds as inhibitors of
 oxidosqualene cyclase.
 INVENTOR(S): Brown, George Robert; Newcombe, Nicholas John;
 Stokes,
 Elaine Sophie Elizabeth; Waterson, David
 PATENT ASSIGNEE(S): Zeneca Limited, UK; Brown, George Robert; Newcombe,
 Nicholas John; Stokes, Elaine Sophie Elizabeth;
 Waterson, David
 SOURCE: PCT Int. Appl., 91 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 9806705 | A1 | 19980219 | WO 1997-GB2029 | 19970725 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US,
UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
GN, ML, MR, NE, SN, TD, TG | | | | |
| AU 9737017 | A1 | 19980306 | AU 1997-37017 | 19970725 |
| EP 925286 | A1 | 19990630 | EP 1997-933774 | 19970725 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI | | | | |
| BR 9711135 | A | 19990817 | BR 1997-11135 | 19970725 |
| CN 1228087 | A | 19990908 | CN 1997-197282 | 19970725 |
| JP 2000516602 | T2 | 20001212 | JP 1998-509469 | 19970725 |
| NO 9900663 | A | 19990412 | NO 1999-663 | 19990212 |
| US 6093718 | A | 20000725 | US 1999-242309 | 19990212 |
| PRIORITY APPLN. INFO.: | | | GB 1996-17060 | 19960814 |
| | | | GB 1997-3027 | 19970214 |
| | | | WO 1997-GB2029 | 19970725 |

OTHER SOURCE(S): MARPAT 128:192661
 GI



AB Title compds. [I; T1, T3 = N, CR; R = H, alkyl, alkenyl, alkynyl; R1 = H, amino, halo, cyano, alkyl, alkylamino, dialkylamino, alkoxy; m = 1, 2; T2 = CH, N; Q = (substituted) Ph, naphthyl, phenylalkenyl, heteroaryl; Q1 = (CH₂)_a; Q2 = (CH₂)_b; Q3 = (CH₂)_c; Q4 = (CH₂)_d; X = O, CO, S, SO, SO₂,

CH₂; a, b = 2, 3; c, d = 1, 2], were prepd. as antihypercholesteremics. Thus, 4-[1-(4-pyrimidinyl)piperazin-4-ylcarbonyl]piperidine in CH₂Cl₂ was treated with a mixt. of 4-chlorophenylsulfonyl chloride and Et₃N in

CH₂Cl₂ under ice cooling followed by stirring for 18 h at room temp. to give 26% 1-(4-chlorophenylsulfonyl)-4-[1-(4-pyrimidinyl)piperazin-4-ylcarbonyl]piperidine. The latter at 5 mg/kg orally in rats gave 72% inhibition of cholesterol biosynthesis.

IT 179050-27-2P 179050-28-3P 179050-48-7P
 179050-49-8P 188526-43-4P 188526-44-5P
 188526-45-6P 188526-46-7P 188526-47-8P
 188526-48-9P 188526-49-0P 188526-50-3P
 188526-51-4P 188526-52-5P 188526-53-6P
 188526-54-7P 188526-55-8P 188526-56-9P
 188526-57-0P 188526-58-1P 188526-59-2P
 188526-60-5P 188526-61-6P 188526-62-7P
 188526-63-8P 188526-65-0P 188526-66-1P
 188526-67-2P 188526-68-3P 188526-69-4P
 188526-70-7P 188526-71-8P 188526-76-3P
 188526-77-4P 188526-78-5P 188526-79-6P
 188526-80-9P 188526-81-0P 188526-82-1P
 188526-83-2P 188526-84-3P 188526-85-4P
 188526-86-5P 188526-87-6P 188526-88-7P
 188526-89-8P 188526-93-4P 188526-95-6P
 188526-96-7P 203522-46-7P 203522-48-9P
 203522-51-4P 203522-53-6P 203522-54-7P
 203522-55-8P 203522-78-5P 203522-79-6P
 203522-80-9P 203522-81-0P 203522-83-2P
 203522-85-4P 203522-87-6P 203522-89-8P
 203522-93-4P 203522-96-7P 203522-97-8P
 203522-98-9P 203523-00-6P 203523-02-8P
 203523-05-1P 203523-06-2P 203574-71-4P
 203574-72-5P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of pyrimidinylpiperidinylcarbonylpiperazines and related compds. as inhibitors of oxidosqualene cyclase)

RN 179050-27-2 CAPLUS

CN Piperazine,


1-[[1-(2-amino-6-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-(2-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 179050-28-3 CAPLUS


CN Piperazine,
1-[{2-(4-chlorophenyl)ethenyl}sulfonyl]-4-[(1-(4-pyrimidinyl)-
4-piperidinyl)carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 179050-48-7 CAPLUS

CN Piperazine,
1-[{(6-chloro-2-naphthalenyl)sulfonyl}-4-[(1-(4-pyrimidinyl)-4-
piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-49-8 CAPLUS


CN Piperazine, 1-[(1-(2-amino-4-pyrimidinyl)-4-piperidinyl)carbonyl]-4-[(6-
chloro-2-naphthalenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 188526-43-4 CAPLUS
 CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-44-5 CAPLUS
 CN Piperazine,
 1-(phenylmethyl)-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-
 (9CI) (CA INDEX NAME)



RN 188526-45-6 CAPLUS
 CN Piperazine, 1-[(4-cyanophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-46-7 CAPLUS
 CN Piperazine, 1-[(2-chloro-4-cyanophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-47-8 CAPLUS

CN Piperazine, 1-[(3,4-dichlorophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-48-9 CAPLUS

CN Piperazine, 1-[(4-methoxyphenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-49-0 CAPLUS

CN Piperazine, 1-[(4-chlorophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-50-3 CAPLUS

CN Piperazine, 1-[(2-cyanophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-51-4 CAPLUS

CN Piperazine, 1-[(2,4-difluorophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-52-5 CAPLUS

CN Piperazine, 1-[(4-butoxyphenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-53-6 CAPLUS

CN Piperazine, 1-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-54-7 CAPLUS

CN Piperazine, 1-[[4-(1-methylethyl)phenyl]sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-55-8 CAPLUS

CN Piperazine, 1-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]-4-(2-thienylsulfonyl)- (9CI) (CA INDEX NAME)




RN 188526-56-9 CAPLUS

CN Piperazine, 1-[(5-chloro-2-thienyl)sulfonyl]-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-57-0 CAPLUS

CN Piperazine, 1-[(2,5-dichloro-3-thienyl)sulfonyl]-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-58-1 CAPLUS

CN Piperazine, 1-[(5-bromo-2-thienyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-59-2 CAPLUS

CN Piperazine, 1-[(4,5-dibromo-2-thienyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-60-5 CAPLUS

CN Piperazine, 1-[(4,5-dichloro-2-thienyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-61-6 CAPLUS

CN Piperazine, 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 188526-62-7 CAPLUS


CN Piperazine, 1-[(5-(2-pyridinyl)-2-thienyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-63-8 CAPLUS

CN Piperazine, 1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 188526-65-0 CAPLUS

CN Piperazine, 1-[(4-fluoro-3,5-dimethylphenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-66-1 CAPLUS

CN Piperazine, 1-[(3,6-dibromo-2,5-difluorophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-67-2 CAPLUS

CN Piperazine, 1-[(4-iodophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-68-3 CAPLUS

CN Acetamide, N-[4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-1-piperazinyl]sulfonylphenyl]- (9CI) (CA INDEX NAME)




RN 188526-69-4 CAPLUS

CN Piperazine, 1-(phenylsulfonyl)-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-70-7 CAPLUS

CN Piperazine, 1-[(4-ethylphenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-71-8 CAPLUS

CN Piperazine, 1-[(4-propylphenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-76-3 CAPLUS

CN Piperazine, 1-[(4-methylphenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-77-4 CAPLUS

CN Piperazine, 1-[(2,5-dibromophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-78-5 CAPLUS

CN Piperazine, 1-[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-79-6 CAPLUS

CN Piperazine, 1-[(4-nitrophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-80-9 CAPLUS

CN Piperazine, 1-[(4-chloro-3-nitrophenyl)sulfonyl]-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl] - (9CI) (CA INDEX NAME)




RN 188526-81-0 CAPLUS

RN 100-20-01 CN 00000000000000000000000000000000
CN Benzoic acid, 2-[[4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-1-piperazinyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 188526-82-1 CAPLUS


RN 16636-32-1 CAS#55
CN Piperazine, 1-[(3,4-dibromophenyl) sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl] carbonyl] - (9CI) (CA INDEX NAME)




RN 188526-83-2 CAPLUS
 CN Piperazine, 1-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]-4-[(2,4,5-trichlorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 188526-84-3 CAPLUS
 CN Piperazine, 1-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]-4-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 188526-85-4 CAPLUS
 CN Piperazine, 1-[(3,5-dichlorophenyl)sulfonyl]-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-86-5 CAPLUS
 CN Piperazine,
 1-[(2-chloro-4-fluorophenyl)sulfonyl]-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-87-6 CAPLUS
 CN Piperazine, 1-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]-4-[(4-(trifluoromethoxy)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 188526-88-7 CAPLUS
 CN Piperazine, 1-[(2-chloro-4-(trifluoromethyl)phenyl)sulfonyl]-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 188526-89-8 CAPLUS
 CN 2-Piperazinecarboxylic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 188526-93-4 CAPLUS
 CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[(1-(5-chloro-4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-95-6 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-96-7 CAPLUS

CN Piperazine, 1-[(4-fluorophenyl)sulfonyl]-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-46-7 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[(4-methyl-1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-48-9 CAPLUS

CN Piperazine, 1-[(1-(2,6-dimethyl-4-pyrimidinyl)-4-piperidinyl)carbonyl]-4-[(4-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 203522-51-4 CAPLUS

CN Piperazine, 1-[(1-(2,6-dimethyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 203522-53-6 CAPLUS

CN Piperazine, 1-[(4-chlorophenyl)sulfonyl]-4-[(1-(2,6-dimethyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-54-7 CAPLUS

CN Piperazine, 1-[(1-(2,6-dimethyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-[(4-(trifluoromethyl)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 203522-55-8 CAPLUS

CN Piperazine, 1-[(2-chloro-4-(trifluoromethyl)phenyl)sulfonyl]-4-[[1-(2,6-dimethyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-78-5 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(2-propyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-79-6 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(2-ethyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-80-9 CAPLUS

CN Piperazine, 1-[(4-chlorophenyl)sulfonyl]-4-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-81-0 CAPLUS


CN Piperazine,
 1-[(4-fluorophenyl)sulfonyl]-4-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-83-2 CAPLUS
 CN Piperazine, 1-[(3-chloro-4-fluorophenyl)sulfonyl]-4-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-85-4 CAPLUS
 CN Piperazine,
 1-[(3-fluorophenyl)sulfonyl]-4-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 203522-87-6 CAPLUS
 CN Piperazine, 1-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-[(4-(trifluoromethyl)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 203522-89-8 CAPLUS
 CN Piperazine, 1-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-(2-thienylsulfonyl)- (9CI) (CA INDEX NAME)




RN 203522-93-4 CAPLUS

CN Piperazine, 1-[(5-chloro-2-thienyl)sulfonyl]-4-[[1-(2,6-dimethyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-96-7 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(2-ethyl-4-pyrimidinyl)-4-methyl-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-97-8 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[4-ethyl-1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-98-9 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[(1-(2-methyl-4-pyrimidinyl)-4-(2-propenyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 203523-00-6 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[(4-methyl-1-(2-methyl-4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 203523-02-8 CAPLUS

CN Piperazine, 1-[(1-(6-methyl-4-pyrimidinyl)-4-piperidinyl)carbonyl]-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 203523-05-1 CAPLUS


CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[(1-[6-(methylamino)-4-pyrimidinyl]-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 203523-06-2 CAPLUS

CN Piperazine,

1-[[1-[6-(methylamino)-4-pyrimidinyl]-4-piperidinyl]carbonyl]-
4-[(4-(trifluoromethyl)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 203574-71-4 CAPLUS



CN Piperazine, 1-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-[(2,2,2-trifluoroethyl)phenylsulfonyl]- (9CI) (CA INDEX NAME)



F₃C—CH₂—D1



CN Piperazine, 1-[(2-chlorothienyl)sulfonyl]-4-[[1-(2,6-dimethyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




IT 203520-91-6P 203520-93-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of pyrimidinylpiperidinylcarbonylpiperazines and related
 compds. as inhibitors of oxidosqualene cyclase)


RN 203520-91-6 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[(1-(6-chloro-4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 203520-93-8 CAPLUS

CN Piperazine, 1-[(1-(6-chloro-4-pyrimidinyl)-4-piperidinyl)carbonyl]-4-[(4-(trifluoromethyl)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1997:542445 CAPLUS

DOCUMENT NUMBER: 127:234328

TITLE: Preparation of pyridylpiperidinylcarbonylpiperazines
 and related compounds as antithrombotics/anticoagulant

S.

INVENTOR(S): Faull, Alan Wellington

PATENT ASSIGNEE(S): Zeneca Ltd., UK; Faull, Alan Wellington

SOURCE: PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 9729104 | A1 | 19970814 | WO 1997-GB270 | 19970131 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,
MR, NE, SN, TD, TG | | | | |
| AU 9715534 | A1 | 19970828 | AU 1997-15534 | 19970131 |
| EP 880516 | A1 | 19981202 | EP 1997-901728 | 19970131 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO | | | | |
| JP 20000504682 | T2 | 20000418 | JP 1997-528261 | 19970131 |
| US 6022869 | A | 20000208 | US 1998-117673 | 19980804 |
| PRIORITY APPLN. INFO.: | | | GB 1996-2294 | 19960205 |
| | | | WO 1997-GB270 | 19970131 |


OTHER SOURCE(S): MARPAT 127:234328

GI




AB Title compds. [I; T1, G1, G2 = CH, N; R1 = halo, CF3, OCF3, cyano, amino, OH, NO2, alkyl, alkoxy; L1 = (substituted) alkylene, 1,2-cycloalkylene, alkylene carbonyl; R2, R3 = H, alkyl; R2R3 = (substituted) alkylene, methylene carbonyl; R4 = CONR7(CH2)nSOpR8, CONH(CH2)qNR9R10, AY1; R7 = H; R8 = alkyl, Ph, phenylalkyl; R7R8 = alkylene; R9, R10 = H, alkyl, Ph, alkylphenyl, SOpR8, heteroaryl, COR11; R11 = H, alkyl, Ph, alkylphenyl; R14-R16 = H, alkyl; A = alkylene; Y1 = SOpR8, NHSO2R8, pyrrolidin-1-yl, piperidino, morpholino, piperazin-1-yl, etc.; m, p = 0-2; q = 2-4; X1 = O, S, SO, SO2, CO, CO2, CONR14, CR15R16; Q = (substituted) Ph, naphthyl, phenylalkyl, heterocycllyl], were prepd. Thus, 4-(6-bromonaphth-2-ylsulfonyl)-2-carboxy-1-[1-(4-pyridyl)piperidin-4-ylcarbonyl]piperazine (prepn. given) in DMF was treated with N-3-dimethylaminopropyl-N-ethylcarbodiimide, 1-hydroxybenzotriazole, and 2-(ethylthio)amine in DMF to give 44% 4-(6-bromonaphth-2-ylsulfonyl)-2-[N-2-(ethylthioethyl)carbamoyl]-1-[1-(4-pyridyl)piperidin-4-ylcarbonyl]piperazine. The latter inhibited Factor Xa with IC50 = 0.004


.mu.M.
 IT 195153-83-4P 195153-84-5P 195153-85-6P
 195153-86-7P 195153-87-8P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of pyridylpiperidinylcarbonylpiperazines and related compds.
 as antithrombotics/anticoagulants)
 RN 195153-83-4 CAPLUS
 CN 2-Piperazinecarboxamide, 4-[(6-bromo-2-naphthalenyl)sulfonyl]-N-[2-(ethylthio)ethyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 195153-84-5 CAPLUS
 CN Thiomorpholine, 4-[(4-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl]carbonyl]-2-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 195153-85-6 CAPLUS
 CN Thiomorpholine, 4-[(4-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl]carbonyl]-2-piperazinyl]carbonyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 195153-86-7 CAPLUS

CN 2-Piperazinecarboxamide, 4-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-N-(tetrahydro-1,1-dioxido-3-thienyl)-(9CI) (CA INDEX NAME)



RN 195153-87-8 CAPLUS

CN 2-Piperazinecarboxamide, 4-[(6-bromo-2-naphthalenyl)sulfonyl]-N-[2-(dimethylamino)ethyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



IT 179050-61-4P 179050-62-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of pyridylpiperidinylcarbonylpiperazines and related compds.


as

antithrombotics/anticoagulants)

RN 179050-61-4 CAPLUS

CN 2-Piperazinecarboxylic acid,


4-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 179050-62-5 CAPLUS

CN 2-Piperazinecarboxylic acid,

4-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1997:259776 CAPLUS



DOCUMENT NUMBER: 126:238391

TITLE: Preparation of (di)azinylcarbonyl(diazines as

INVENTOR(S): oxidosqualene cyclase inhibitors
Elisabeth; Brown, George Robert; Stokes, Elaine Sophie
PATENT ASSIGNEE(S): Waterson, David; Wood, Robin
Zeneca Limited, UK; Brown, George Robert; Stokes,
Elaine Sophie Elisabeth; Waterson, David; Wood, Robin
SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-----------------|----------|
| WO 9706802 | A1 | 19970227 | WO 1996-GB1985 | 19960814 |
| W: | AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,
ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS,
LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | |
| RW: | KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA | | | |
| CA 2226735 | AA | 19970227 | CA 1996-2226735 | 19960814 |
| AU 9667485 | A1 | 19970312 | AU 1996-67485 | 19960814 |
| EP 844877 | A1 | 19980603 | EP 1996-927782 | 19960814 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI | | | |
| CN 1193276 | A | 19980916 | CN 1996-196278 | 19960814 |
| JP 11511161 | T2 | 19990928 | JP 1996-509050 | 19960814 |
| US 6090813 | A | 20000718 | US 1998-11718 | 19980213 |
| PRIORITY APPLN. INFO.: | | | GB 1995-16709 | 19950815 |
| | | | WO 1996-GB1985 | 19960814 |

OTHER SOURCE(S): MARPAT 126:238391
GI




II

AB Title compds. [I; A = bond or alkylene; G, T1-T3 = CH or N (T2 .noteq. T3 = CH); Q = cycloalkyl, heterocyclyl, phenyl(alkyl), etc.; R1 = H, halo, NH₂, cyano, alkyl, alkoxy; X = O, SOO-2, CO, CONH, etc.; G1, G2 = 1 or 2 CH₂; G3, G4 = 0 or 1 CH₂; m = 1 or 2] were prepd. Thus, 1-(4-pyridyl)piperidine-4-carbonyl chloride (prepn. given) was amidated by 3-methyl-1-(2-naphthylsulfonyl)piperazine to give title compd. II. Data for biol. activity of 1 prepd. I were given.

IT 179049-56-0P 179049-81-1P 179049-82-2P
 179049-93-5P 179049-94-6P 179049-95-7P
 179049-96-8P 179049-98-0P 179049-99-1P
 179050-00-1P 179050-03-4P 179050-05-6P
 179050-06-7P 179050-07-8P 179050-09-0P
 179050-10-3P 179050-11-4P 179050-12-5P
 179050-23-8P 179050-27-2P 179050-28-3P
 179050-30-7P 179050-31-8P 179050-34-1P
 179050-40-9P 179050-42-1P 179050-46-5P
 179050-48-7P 179050-49-8P 188526-29-6P
 188526-30-9P 188526-31-0P 188526-32-1P
 188526-33-2P 188526-34-3P 188526-35-4P
 188526-36-5P 188526-38-7P 188526-41-2P
 188526-42-3P 188526-43-4P 188526-44-5P
 188526-45-6P 188526-46-7P 188526-47-8P
 188526-48-9P 188526-49-0P 188526-50-3P
 188526-51-4P 188526-52-5P 188526-53-6P
 188526-54-7P 188526-55-8P 188526-56-9P
 188526-57-0P 188526-58-1P 188526-59-2P
 188526-60-5P 188526-61-6P 188526-62-7P
 188526-63-8P 188526-64-9P 188526-65-0P
 188526-66-1P 188526-67-2P 188526-68-3P
 188526-69-4P 188526-70-7P 188526-71-8P
 188526-72-9P 188526-73-0P 188526-74-1P
 188526-75-2P 188526-76-3P 188526-77-4P
 188526-78-5P 188526-79-6P 188526-80-9P
 188526-81-0P 188526-82-1P 188526-83-2P
 188526-84-3P 188526-85-4P 188526-86-5P
 188526-87-6P 188526-88-7P 188526-89-8P
 188526-93-4P 188526-95-6P 188526-96-7P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of (di)azinylcarbonyl(di)azines as oxidosqualene cyclase inhibitors)

RN 179049-56-0 CAPLUS
 CN Piperazine, 1-(2-naphthalenylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179049-81-1 CAPLUS

CN Piperazine, 1-[(8-chloro-2-naphthalenyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 179049-82-2 CAPLUS


CN 2-Piperazinecarboxylic acid, 1-(2-naphthalenylsulfonyl)-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 179049-93-5 CAPLUS

CN Piperazine, 1-[(2-(4-methylphenyl)ethenyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179049-94-6 CAPLUS

CN Piperazine,
1-[[2-(2-methylphenyl)ethenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179049-95-7 CAPLUS

CN Piperazine,
1-[[2-(4-fluorophenyl)ethenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179049-96-8 CAPLUS

CN Piperazine,
1-[[2-(2-chlorophenyl)ethenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179049-98-0 CAPLUS

CN Piperazine, 1-[{2-[(3,4-dichlorophenyl)ethenyl]sulfonyl}-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179049-99-1 CAPLUS

CN Piperazine, 1-[{2-[(4-bromophenyl)ethenyl]sulfonyl}-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179050-00-1 CAPLUS


CN Piperazine, 1-[{1-(4-pyridinyl)-4-piperidinyl}carbonyl]-4-[[2-[(4-(trifluoromethyl)phenyl)ethenyl]sulfonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 179050-03-4 CAPLUS

CN Piperazine, 1-[(7-ethoxy-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-05-6 CAPLUS

CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-06-7 CAPLUS


CN Piperazine, 1-[(6-bromo-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-07-8 CAPLUS
 CN Piperazine, 1-[(6-methoxy-2-naphthalenyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-09-0 CAPLUS
 CN Piperazine, 1-[(6-fluoro-2-naphthalenyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-10-3 CAPLUS
 CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-11-4 CAPLUS

CN Piperazine, 1-[(1,1'-biphenyl)-4-ylsulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-12-5 CAPLUS

CN Piperazine, 1-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-23-8 CAPLUS

CN Piperazine, 2-methyl-4-(2-naphthalenylsulfonyl)-1-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-27-2 CAPLUS


CN Piperazine,
1-[(1-(2-amino-6-methyl-4-pyrimidinyl)-4-piperidinyl)carbonyl]-
4-(2-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 179050-28-3 CAPLUS


CN Piperazine,
1-[2-(4-chlorophenyl)ethenyl]sulfonyl]-4-[(1-(4-pyrimidinyl)-
4-piperidinyl)carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 179050-30-7 CAPLUS

CN Piperazine,
1-[(4'-bromo[1,1'-biphenyl]-4-yl)sulfonyl]-4-[(1-(4-pyridinyl)-
4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-31-8 CAPLUS

CN Piperazine, 1-[(3',5'-dichloro[1,1'-biphenyl]-4-yl)sulfonyl]-4-[(1-(4-
pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-34-1 CAPLUS

CN Piperazine, 1-[(4-iodophenyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-40-9 CAPLUS

CN Piperazine, 1-[(4-(2-pyridinyl)phenyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-42-1 CAPLUS


CN 2-Piperazinecarboxylic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 179050-46-5 CAPLUS


CN Piperazine, 1-(2-naphthalenylsulfonyl)-2-(phenylmethyl)-4-[(1-(4-

pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-48-7 CAPLUS

CN Piperazine,
1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-49-8 CAPLUS

CN Piperazine, 1-[[1-(2-amino-4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-[(6-chloro-2-naphthalenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 188526-29-6 CAPLUS

CN Piperazine,
1-[(4-fluoro-3,5-dimethylphenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 188526-30-9 CAPLUS


CN Piperazine, 1-[(4-fluorophenyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-31-0 CAPLUS

CN Piperazine, 1-[(5-(dimethylamino)-1-naphthalenyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 188526-32-1 CAPLUS

CN Piperazine, 1-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]-4-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 188526-33-2 CAPLUS

CN Piperazine, 1-[(2-nitrophenyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-34-3 CAPLUS

CN Piperazine, 1-(phenylsulfonyl)-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-35-4 CAPLUS

CN Piperazine, 1-[(5-chloro-2-naphthalenyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-36-5 CAPLUS

CN Piperazine, 1-[(3-bromophenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-38-7 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)methyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-41-2 CAPLUS

CN Piperazine, 1-[(4-cyanophenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-42-3 CAPLUS


CN Piperazine, 1-[(4-bromophenyl)methyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-43-4 CAPLUS
 CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[(1-(2-methyl-4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-44-5 CAPLUS
 CN Piperazine,
 1-(phenylmethyl)-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]-
 (9CI) (CA INDEX NAME)



RN 188526-45-6 CAPLUS
 CN Piperazine, 1-[(4-cyanophenyl)sulfonyl]-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-46-7 CAPLUS
 CN Piperazine, 1-[(2-chloro-4-cyanophenyl)sulfonyl]-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-47-8 CAPLUS

CN Piperazine, 1-[(3,4-dichlorophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-48-9 CAPLUS

CN Piperazine, 1-[(4-methoxyphenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-49-0 CAPLUS

CN Piperazine, 1-[(4-chlorophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-50-3 CAPLUS

CN Piperazine, 1-[(2-cyanophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-51-4 CAPLUS

CN Piperazine, 1-[(2,4-difluorophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-52-5 CAPLUS

CN Piperazine, 1-[(4-butoxyphenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-53-6 CAPLUS

CN Piperazine, 1-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-54-7 CAPLUS

CN Piperazine,
1-[[4-(1-methylethyl)phenyl]sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-55-8 CAPLUS

CN Piperazine, 1-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]-4-(2-thienylsulfonyl)- (9CI) (CA INDEX NAME)




RN 188526-56-9 CAPLUS

CN Piperazine, 1-[(5-chloro-2-thienyl)sulfonyl]-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-57-0 CAPLUS

CN Piperazine, 1-[(2,5-dichloro-3-thienyl)sulfonyl]-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-58-1 CAPLUS

CN Piperazine, 1-[(5-bromo-2-thienyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-59-2 CAPLUS

CN Piperazine, 1-[(4,5-dibromo-2-thienyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-60-5 CAPLUS

CN Piperazine, 1-[(4,5-dichloro-2-thienyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-61-6 CAPLUS

CN Piperazine, 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 188526-62-7 CAPLUS


CN Piperazine, 1-[(5-(2-pyridinyl)-2-thienyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-63-8 CAPLUS

CN Piperazine, 1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 188526-64-9 CAPLUS

CN Piperazine, 1-(cyclohexylsulfonyl)-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-65-0 CAPLUS

CN Piperazine, 1-[(4-fluoro-3,5-dimethylphenyl)sulfonyl]-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-66-1 CAPLUS

CN Piperazine, 1-[(3,6-dibromo-2,5-difluorophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-67-2 CAPLUS

CN Piperazine, 1-[(4-iodophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-68-3 CAPLUS

CN Acetamide, N-[4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-1-piperazinyl]sulfonylphenyl]- (9CI) (CA INDEX NAME)




RN 188526-69-4 CAPLUS

CN Piperazine, 1-(phenylsulfonyl)-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-70-7 CAPLUS

CN Piperazine, 1-[(4-ethylphenyl)sulfonyl]-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-71-8 CAPLUS

CN Piperazine, 1-[(4-propylphenyl)sulfonyl]-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-72-9 CAPLUS

CN Piperazine, 1-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]-4-[(2,2,2-trifluoroethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 188526-73-0 CAPLUS

CN Piperazine, 1-(butylsulfonyl)-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-74-1 CAPLUS

CN Piperazine, 1-[(1-methylethyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-75-2 CAPLUS

CN Piperazine, 1-(methylsulfonyl)-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 188526-76-3 CAPLUS


CN Piperazine, 1-[(4-methylphenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 188526-77-4 CAPLUS


CN Piperazine, 1-[(2,5-dibromophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-

piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-78-5 CAPLUS

CN Piperazine, 1-[(3,5-bis(trifluoromethyl)phenyl)sulfonyl]-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-79-6 CAPLUS

CN Piperazine, 1-[(4-nitrophenyl)sulfonyl]-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-80-9 CAPLUS

CN Piperazine, 1-[(4-chloro-3-nitrophenyl)sulfonyl]-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-81-0 CAPLUS

CN Benzoic acid, 2-[[4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]-1-piperazinyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 188526-82-1 CAPLUS

CN Piperazine, 1-[(3,4-dibromophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-83-2 CAPLUS

CN Piperazine, 1-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-[(2,4,5-trichlorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 188526-84-3 CAPLUS


CN Piperazine, 1-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 188526-85-4 CAPLUS


CN Piperazine, 1-[(3,5-dichlorophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-

piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-86-5 CAPLUS

CN Piperazine,
1-[(2-chloro-4-fluorophenyl)sulfonyl]-4-[(1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-87-6 CAPLUS

CN Piperazine, 1-[(1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-[(4-(trifluoromethoxy)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 188526-88-7 CAPLUS

CN Piperazine, 1-[(2-chloro-4-(trifluoromethyl)phenyl)sulfonyl]-4-[(1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-89-8 CAPLUS


CN 2-Piperazinecarboxylic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[(1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 188526-93-4 CAPLUS
 CN Piperazine, 1-[(4-bromophenyl) sulfonyl]-4-[(1-(5-chloro-4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 188526-95-6 CAPLUS
 CN Piperazine, 1-[(4-bromophenyl) sulfonyl]-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-96-7 CAPLUS
 CN Piperazine, 1-[(4-fluorophenyl) sulfonyl]-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)



IT 179051-10-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of (di)azinylcarbonyl(di)azines as oxidosqualene cyclase
 inhibitors)
 RN 179051-10-6 CAPLUS
 CN 2-Piperazinecarboxylic acid, 1-(phenylmethyl)-4-[(1-(4-pyridinyl)-4-

piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 1996:455760 CAPLUS
 DOCUMENT NUMBER: 125:114690
 TITLE: Preparation of aminoheterocyclic derivatives as antithrombotic or anticoagulant agents
 INVENTOR(S): Faull, Alan Wellington; Mayo, Colette Marie; Preston, John; Stocker, Andrew
 PATENT ASSIGNEE(S): Zeneca Limited, UK
 SOURCE: PCT Int. Appl., 161 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 9610022 | A1 | 19960404 | WO 1995-GB2285 | 19950925 |
| W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM | | | | |
| RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| CA 2197471 | AA | 19960404 | CA 1995-2197471 | 19950925 |
| AU 9535307 | A1 | 19960419 | AU 1995-35307 | 19950925 |
| AU 696491 | B2 | 19980910 | | |
| EP 783500 | A1 | 19970716 | EP 1995-932128 | 19950925 |
| EP 783500 | B1 | 19980722 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, | | | | |
| SE | | | | |
| BR 9509045 | A | 19970930 | BR 1995-9045 | 19950925 |
| CN 1164232 | A | 19971105 | CN 1995-196337 | 19950925 |
| JP 10506122 | T2 | 19980616 | JP 1995-511499 | 19950925 |
| AT 168685 | E | 19980815 | AT 1995-932128 | 19950925 |
| HU 77769 | A2 | 19980828 | HU 1997-2052 | 19950925 |
| ES 2119472 | T3 | 19981001 | ES 1995-932128 | 19950925 |
| CZ 285370 | B6 | 19990714 | CZ 1997-893 | 19950925 |
| ZA 9508085 | A | 19960424 | ZA 1995-8085 | 19950926 |
| NO 9701415 | A | 19970522 | NO 1997-1415 | 19970325 |


US 5965559
PRIORITY APPLN. INFO.:

A 19991012


US 1997-817031
GB 1994-19341
GB 1994-25789
GB 1995-11051
WO 1995-GB2285

19970326
19940926
19941221
19950601
19950925

OTHER SOURCE(S): MARPAT 125:114690
GI



I



II

AB The title compds. [I; G1, G2, G3 = CH, N; m = 1, 2; R1 = H, halo, C1-4 alkyl; M1 = (substituted) piperidino, piperazino, etc.; A = bond, C1-4 alkylene; M2 = piperazino, etc.; M3 = bond, etc.; X = SO2; Q = naphthyl, heterocyclyl] were prep'd. and formulated. Treatment of 1-(4-pyridyl)piperidine-4-carboxylic acid with SOC12 followed by addn. of 1-tert-butoxycarbonylpiperazine, deprotection of the intermediate II (Y = Boc) with HCl/Et2O and reaction of piperazine II.3HCl (Y = H) with 2-naphthylsulfonyl chloride afforded I [G1, G2, G3 = CH; R1 = H; M1 = piperidino; A, M3 = bond; M2 = piperazino; X = SO2; Q = 2-naphthyl]. In general, compds. I showed IC50 of 0.001-25 .mu.M against Factor Xa and of > 50 .mu.M against thrombin.


IT 179050-42-1P

RL: BAC (Biological activity or effector, except adverse); RCT
(Reactant);

SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amineheterocyclic derivs. as antithrombotic or anticoagulant agents)

RN 179050-42-1 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 179049-56-0P 179049-65-1P 179049-81-1P
 179049-82-2P 179049-91-3P 179049-92-4P
 179049-93-5P 179049-94-6P 179049-95-7P
 179049-96-8P 179049-97-9P 179049-98-0P
 179049-99-1P 179050-00-1P 179050-01-2P
 179050-02-3P 179050-03-4P 179050-04-5P
 179050-05-6P 179050-06-7P 179050-07-8P
 179050-08-9P 179050-09-0P 179050-10-3P
 179050-11-4P 179050-12-5P 179050-13-6P
 179050-14-7P 179050-15-8P 179050-17-0P
 179050-22-7P 179050-23-8P 179050-24-9P
 179050-25-0P 179050-26-1P 179050-27-2P
 179050-28-3P 179050-29-4P 179050-30-7P
 179050-31-8P 179050-32-9P 179050-33-0P
 179050-34-1P 179050-35-2P 179050-36-3P
 179050-37-4P 179050-38-5P 179050-39-6P
 179050-40-9P 179050-41-0P 179050-43-2P
 179050-44-3P 179050-45-4P 179050-46-5P
 179050-48-7P 179050-49-8P 179050-50-1P
 179050-51-2P 179050-56-7P 179050-58-9P
 179050-59-0P 179050-60-3P 179050-61-4P
 179050-62-5P 179050-63-6P 179050-65-8P
 179050-66-9P 179050-69-2P 179051-81-1P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aminoheterocyclic derivs. as antithrombotic or anticoagulant agents)

RN 179049-56-0 CAPLUS


CN Piperazine, 1-(2-naphthalenylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179049-65-1 CAPLUS

CN Piperazine, 1-(1-naphthalenylsulfonyl)-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 179049-81-1 CAPLUS

CN Piperazine, 1-[(8-chloro-2-naphthalenyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 179049-82-2 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-(2-naphthalenylsulfonyl)-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 179049-91-3 CAPLUS


CN Piperazine, 1-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]-4-[(5-(2-pyridinyl)-2-thienyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 179049-92-4 CAPLUS

CN Piperazine, 1-[[2-(4-chlorophenyl)ethenyl]sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179049-93-5 CAPLUS

CN Piperazine,
1-[(2-(4-methylphenyl)ethenyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179049-94-6 CAPLUS

CN Piperazine,
1-[(2-(2-methylphenyl)ethenyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179049-95-7 CAPLUS

CN Piperazine,
1-[(2-(4-fluorophenyl)ethenyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 179049-96-8 CAPLUS

CN Piperazine,

1-[(2-(2-chlorophenyl)ethenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 179049-97-9 CAPLUS

CN Piperazine,

1-[(2-(3-chlorophenyl)ethenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179049-98-0 CAPLUS

CN Piperazine, 1-[(2-(3,4-dichlorophenyl)ethenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179049-99-1 CAPLUS

CN Piperazine, 1-[(2-(4-bromophenyl)ethenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179050-00-1 CAPLUS


CN Piperazine, 1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-4-[[2-[4-(trifluoromethyl)phenyl]ethenyl]sulfonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 179050-01-2 CAPLUS


CN Piperazine, 1-[(4-chloro-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-02-3 CAPLUS
CN Piperazine, 1-[(7-chloro-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-03-4 CAPLUS
CN Piperazine, 1-[(7-ethoxy-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-04-5 CAPLUS
CN Piperazine,
1-[(6,7-dimethoxy-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-05-6 CAPLUS
 CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-06-7 CAPLUS
 CN Piperazine, 1-[(6-bromo-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-07-8 CAPLUS
 CN Piperazine, 1-[(6-methoxy-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-08-9 CAPLUS
 CN Piperazine, 1-[(7-methoxy-2-naphthalenyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-09-0 CAPLUS
 CN Piperazine, 1-[(6-fluoro-2-naphthalenyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-10-3 CAPLUS
 CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-11-4 CAPLUS

CN Piperazine, 1-([1,1'-biphenyl]-4-ylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-12-5 CAPLUS

CN Piperazine, 1-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-13-6 CAPLUS

CN Piperazine, 1-(3-dibenzofuranylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-14-7 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-(2-naphthalenylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-15-8 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-(2-naphthalenylsulfonyl)-1-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 179050-17-0 CAPLUS


CN Piperazinone, 1-(2-naphthalenylmethyl)-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-22-7 CAPLUS


CN Piperazine, 2,5-dimethyl-1-(2-naphthalenylsulfonyl)-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 179050-23-8 CAPLUS

CN Piperazine, 2-methyl-4-(2-naphthalenylsulfonyl)-1-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-24-9 CAPLUS


CN Piperazine, 2-methyl-1-(2-naphthalenylsulfonyl)-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-25-0 CAPLUS


CN Piperazine, 4-[(2-(4-chlorophenyl)ethenyl)sulfonyl]-2-methyl-1-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 179050-26-1 CAPLUS

CN Piperazine, 1-(2-naphthalenylsulfonyl)-4-[(1-(4-pyrimidinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-27-2 CAPLUS

CN Piperazine,


1-[[1-(2-amino-6-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]-
4-(2-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)

RN 179050-28-3 CAPLUS

CN Piperazine,


1-[[2-(4-chlorophenyl)ethenyl]sulfonyl]-4-[[1-(4-pyrimidinyl)-
4-piperidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 179050-29-4 CAPLUS


CN Piperazine, 1-[(4'-methyl[1,1'-biphenyl]-4-yl)sulfonyl]-4-[[1-(4-
pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-30-7 CAPLUS


CN Piperazine,

1-[(4'-bromo[1,1'-biphenyl]-4-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-31-8 CAPLUS

CN Piperazine, 1-[(3',5'-dichloro[1,1'-biphenyl]-4-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-32-9 CAPLUS

CN Piperazine, 1-[(4'-chloro[1,1'-biphenyl]-3-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-33-0 CAPLUS


CN Piperazine, 1-((1,1'-biphenyl)-3-ylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-34-1 CAPLUS
 CN Piperazine, 1-[(4-iodophenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-35-2 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxylic acid, 4'--[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-1-piperazinylsulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 179050-36-3 CAPLUS
 CN Piperazine, 1-[(4'-cyano[1,1'-biphenyl]-4-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-37-4 CAPLUS
 CN Piperazine, 1-[(3',5'-dichloro[1,1'-biphenyl]-3-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-38-5 CAPLUS

CN Piperazine,


1-[(4'-nitro[1,1'-biphenyl]-4-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-39-6 CAPLUS


CN Piperazine,

1-[(4'-chloro-2'-nitro[1,1'-biphenyl]-4-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-40-9 CAPLUS

CN Piperazine, 1-[[4-(2-pyridinyl)phenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-41-0 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[(2-naphthalenylsulfonyl)-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-43-2 CAPLUS


CN 2-Piperazinecarboxylic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-44-3 CAPLUS

CN Piperazine,


4-(2-naphthalenylsulfonyl)-2-(1-piperidinylcarbonyl)-1-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-45-4 CAPLUS


CN Piperazine,

1-(2-naphthalenylsulfonyl)-2-(1-piperidinylcarbonyl)-4-[(1-(4-pyridinyl)-1-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-46-5 CAPLUS

CN Piperazine, 1-(2-naphthalenylsulfonyl)-2-(phenylmethyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-48-7 CAPLUS

CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-49-8 CAPLUS

CN Piperazine, 1-[[1-(2-amino-4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-[(6-chloro-2-naphthalenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 179050-50-1 CAPLUS

CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[[1-(5,6-dichloro-4-pyridazinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-51-2 CAPLUS

CN Piperazine,
1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridazinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-56-7 CAPLUS

CN 2-Piperazinemethanol, 4-(2-naphthalenylsulfonyl)-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-58-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[[4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-1-piperazinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 179050-59-0 CAPLUS


CN Piperazine, 1-[(6-hydroxy-2-naphthalenyl)sulfonyl]-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na


RN 179050-60-3 CAPLUS

CN 2-Piperazineacetic acid, 1-(2-naphthalenylsulfonyl)-4-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 179050-61-4 CAPLUS

CN 2-Piperazinecarboxylic acid,
 4-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 179050-62-5 CAPLUS

CN 2-Piperazinecarboxylic acid,
 4-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-63-6 CAPLUS

CN Morpholine,
 4-[[4-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-2-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-65-8 CAPLUS

CN Piperazine,

1-[[1-(2-amino-6-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]-
4-[(6-chloro-2-naphthalenyl)sulfonyl]- (9CI) (CA INDEX NAME)


RN 179050-66-9 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 179050-69-2 CAPLUS


CN Glycine, N-[[4-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-2-piperazinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 179051-81-1 CAPLUS

CN Piperazine, 1-[(2-phenylethenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 179051-10-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of aminoheterocyclic derivs. as antithrombotic or
anticoagulant
agents)

RN 179051-10-6 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-(phenylmethyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



=> d his

09/ 582,442

(FILE 'HOME' ENTERED AT 10:05:32 ON 09 JAN 2001)

FILE 'REGISTRY' ENTERED AT 10:05:38 ON 09 JAN 2001

L1 STRUCTURE UPLOADED

L2 18 S L1

L3 375 S L1 FUL

FILE 'CAPLUS' ENTERED AT 10:06:53 ON 09 JAN 2001

L4 8 S L3

=> log y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
| FULL ESTIMATED COST | 36.12 | 170.14 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
| CA SUBSCRIBER PRICE | -4.70 | -4.70 |

STN INTERNATIONAL LOGOFF AT 10:11:31 ON 09 JAN 2001